| abstract |
Provided are antibody fusions wherein a peptide has been incorporated into the constant domain of an antibody. The peptides may be incorporated at hydrophobic regions within the constant domain and/or between proteasomal cleavage sites that are either naturally occurring or introduced. Also provided are antibody fusions wherein a peptide has been attached to the C-terminus of the constant domain of an antibody heavy or light chain through a cleavable linker. Methods for using the antibody fusions include therapeutic applications, such as immune modulation and selective cell killing, and research applications, such as screening assays to identify internalizing antibodies or cytotoxic agents. |